This ADME toxicology testing market report studies various product and technology types. ADME is the abbreviation for absorption, distribution, metabolism, and elimination, a pharmacology and pharmacokinetics term that describes the disposition of a drug or compound inside the human body. ADME comprises a set of four processes that develop the performance of a drug on human tissue, and ADME toxicology testing is applied to create a new drug. The key factors assisting the growth of instruments and assay systems market are enhanced accuracy and predictability of ADME –Tox technology, the shift towards in-vitro assays for toxicological studies, and increasing global adoption of novel ADME toxicology testing instruments and assay systems.
For this study, the global ADME toxicology testing market, based on product type, is segmented into instruments, software solutions, assay systems, reagents, and others. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn, along with the respective compounded annual growth rates (CAGRs) for the period 2016 to 2022, considering 2015 as the base year.
Based on technology type ADME toxicology testing market is segmented as in-vivo and in-vitro; in-vitro technology is bifurcated as biochemical testing and cell testing. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn, along with the respective compounded annual growth rates (CAGRs) for the period 2016 to 2022, considering 2015 as the base year.
The ADME toxicology testing market has been geographically categorized into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, and GCC countries. Market size and forecast for these segments from 2013 to 2022 and their CAGRs for the period 2016 to 2022 are provided in this report.
The primary key players profiled in the ADME toxicology testing market are based on business description, financial health, budget allocation, product portfolio, and news coverage. The key players profiled in this report are Cellartis AB, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Caliper Life Sciences, Inc., Promega Corporation, Life Technologies Corporation, Cyprotex PLC, Beckman Coulter, Inc., Optivia Biotechnology, Inc., Accelrys, Inc., Molecular Discovery Ltd., MultiCASE, Inc., Xceleron, Inc., ACEA Biosciences, Inc., Albany Molecular Research, Inc., and CeeTox, Inc.
Based on the type of product, the global ADME toxicology testing market is segmented as follows:
- Instruments
- Software solutions
- Assays systems
- Reagents
- Others
In 2015, instruments and assay systems accounted for the largest market share in the global ADME toxicology testing market. The key factors assisting the growth of instruments and assay systems market are enhanced accuracy and predictability of ADME –Tox technology, the shift towards in-vitro assays for toxicological studies, and increasing global adoption of novel ADME toxicology testing instruments and assay systems. Toxicity issues remain one of the key reasons why promising drug candidates fail to make it beyond the preclinical and clinical trials at a cost to both the company and, ultimately, the patient. Market experts suggest that introducing toxicology testing earlier in the drug development process appeared to be a large investment when the new drug development costs surpassed USD 1 billion. Thus, this event was one of the key factors responsible for significant growth in the ADME toxicology testing market. In addition, the increasing number of drug targets and volume of assay points in the drug discovery process necessitates the need to identify and eliminate potential hits with high ADME and toxicity profiles.
Based on the type of technology, the ADME toxicology testing market is segmented into:
- In-vitro Tests
- Biochemical Testing
- Cell Testing
- In-vivo Tests
In the base year 2015, the in-vivo tests accounted for the largest share in the market in terms of revenue (USD) due to their efficiency in terms of cost and time over other toxicity testing techniques. With benefits such as increased throughput screening, the ADME toxicology prediction technology is expected to increase shortly. In-vitro technologies are anticipated to project lucrative growth owing to increasing ethical concerns over animal use in clinical trials. Application of ADME toxicity computer modeling is expected to rise because of associated benefits related to increasing throughput screening. The key factors driving the ADME toxicology testing market are enhanced accuracy and predictability of ADME-Tox technology, rising ethical concerns over using animals in clinical trials, growing prominence of cell-based assays in drug discovery and ADME analysis, and rising demand and awareness for cardiotoxicity and cell imaging.
For this study, the global ADME toxicology testing market is categorized into:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- The Middle East and Africa (MEA)
In 2015, North America accounted for the largest share of the global ADME toxicology testing market, followed by Asia-Pacific, Europe, LATAM, and MEA. The key factors assisting the market growth in this region are the supportive government regulations towards new drug development. According to market experts, the reduced number of drug failures due to adopting ADME toxicology testing boosts the demand from pharmaceutical and biotechnology companies. Technological advancements such as the application of in-silico techniques that use computer-based testing methods to get fast results are expected to drive the ADME toxicology testing market in the future. The Asia-Pacific region (comprising Japan, China, and India as major countries) is anticipated to grow at the fastest CAGR during 2016 – 2022. The key factors such as the ongoing shift of research work to low-cost countries, increased government support, and rising collaborations between foreign pharmaceutical companies and local research laboratories.
